Meet the winner of Impact55 2026: CamGene Therapeutics

The winner of HCR Law’s Impact55 2026 programme is CamGene Therapeutics who are using IoT technology to track where insect pests are present.

Cam Gene Therapeutics is a biotechnology company developing RNA‑based medicines to address the underlying cellular dysfunction that causes hearing loss, an area where no restorative treatments currently exist.

Their approach uses lipid‑nanoparticle (LNP) delivered RNA therapies, including mRNA, siRNA, and antisense oligonucleotides, to modulate protein expression and regenerate or protect key cochlear cells, with the goal of creating the first mass‑market therapeutic solution for hearing loss.

Their technology is designed for targeted delivery to the inner ear and aims to halt or even reverse progressive hearing decline, initially alongside cochlear implant surgery and later as a standalone therapy.

You can find out more about CamGene Therapeutics and the work they are doing here: https://camgenetx.com/